Factors supporting evaluation
Confirmed diagnosis and target, complete prior-treatment history, measurable disease and adequate current condition.
CAR-T & regenerative medicine
Advanced treatment access begins with rigorous eligibility review.
Patient education, program matching and China treatment coordination for CAR-T and selected stem-cell pathways—without promising outcomes or bypassing physician judgment.
Gastric CAR-T · CLDN18.2
A new option to evaluate—not a universal fit.
CLDN18.2-targeted CAR-T is being evaluated as a treatment pathway for selected patients with gastric or gastro-oesophageal junction adenocarcinoma after prior standard therapy.
- Confirmed gastric or GEJ adenocarcinoma.
- Failure or intolerance after at least two prior treatment lines.
- CLDN18.2 positivity confirmed through appropriate tissue testing.
- Adequate condition for lymphodepletion, cell therapy and close monitoring.
- Final eligibility depends on physician review, tests and current health.
Eligibility and safety
Who may be evaluated—and when treatment should pause.
A credible review balances disease eligibility with current organ function, infection risk and the ability to tolerate intensive monitoring.
Common safety concerns
Active infection, unstable organ function, severe frailty or uncontrolled complications may require treatment to pause.
Typical coordination pathway
From screening to long-term follow-up.
The exact pathway and timing vary by hospital, treatment platform, manufacturing model and patient status.
Screening
Diagnosis, prior therapy, pathology and clinical status.
Target testing
Confirm target expression such as CLDN18.2 where applicable.
Clinical evaluation
Organ function, infection risk and treatment readiness.
Cell therapy
Collection/manufacturing or other platform-specific preparation.
Monitoring
Infusion, adverse-event monitoring and long-term follow-up.
Two advanced-care pillars
Evidence, safeguards and realistic expectations.
Engineered immune-cell therapy
Established in selected blood cancers and rapidly evolving in autoimmune disease and solid tumours. Risks can include cytokine release syndrome, neurotoxicity, cytopenias and infection.
Program-specific evaluation
Indications, evidence and regulatory status differ greatly by cell type and condition. Only appropriately governed clinical programs should be considered.
End-to-end patient support
Record review, hospital communication, travel, admission, interpretation, recovery support and follow-up coordination.
Coordinated examples
What a coordinated case can look like.
The sequence changes by diagnosis, but every pathway begins with document review and hospital confirmation.
Relapsed disease review
Pathology, treatment response, target expression and current disease burden are reviewed together.
CLDN18.2 pathway
Tissue testing, prior therapy and performance status determine whether specialist assessment is appropriate.
Post-treatment continuity
Monitoring, complications, medicines and local handover are planned before the patient travels home.
Patient reading
Choose the guide that matches the diagnosis.
These educational guides explain the clinical questions to prepare before individual assessment.
Scientific review
A guide to CAR T cell therapies.
Read the structured Chinese overview of foundational T-cell biology, five generations of CAR design, clinical milestones, safety, efficacy, access and future directions.
Open the CAR-T review →2017 → 2026
From first approval to in-vivo engineering.Nature Reviews Immunology · 02 July 2026
The infographic and page are educational. Statistics reflect cited study contexts and must not be interpreted as a personal prediction. CAR-T and stem-cell suitability requires evaluation by a qualified medical team.
Does the patient have recent pathology and treatment records?
Those documents are the starting point for any credible eligibility discussion.
Submit for medical evaluation